Showing results (21-30 of 105) with videos related to
Sort By:
Pageof 11
Journal for Immunotherapy of Cancer|November 16, 2019
Mechanisms regulating PD-L1 expression on tumor and immune cellsShuming Chen, George A Crabill, Theresa S Pritchard, et al.Journal of Immunological Methods|July 23, 2002
Quantitative real-time RT-PCR as a method for monitoring T lymphocyte reactivity to full-length tyrosinase protein in vaccinated melanoma patientsFranck Housseau, Kimberly R Lindsey, Samuel D Oberholtzer, et al.Journal of Molecular Biology|April 27, 2010
Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cellsYili Li, Florence R Depontieu, John Sidney, et al.The New England Journal of Medicine|August 2, 2003
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancerJames C Yang, Leah Haworth, Richard M Sherry, et al.Journal of Proteome Research|August 24, 2016
Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in MelanomaStacy A Malaker, Michael J Ferracane, Florence R Depontieu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2014
Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyJanis M Taube, Alison Klein, Julie R Brahmer, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 16, 2010
Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinomaRichard E Royal, Catherine Levy, Keli Turner, et al.Journal of the National Cancer Institute|July 19, 2011
Opportunities and challenges in the development of experimental drug combinations for cancerRachel W Humphrey, Laura M Brockway-Lunardi, David T Bonk, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 1, 2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced MelanomaSteve Y Cho, Evan J Lipson, Hyung-Jun Im, et al.Nature Immunology|March 6, 2007
Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptorLu Deng, Ries J Langley, Patrick H Brown, et al.Pageof 11